Advertisement

Drugs

, Volume 77, Issue 14, pp 1565–1576 | Cite as

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer

  • Lesley J. Scott
Adis Drug Evaluation

Abstract

Oral abiraterone acetate (Zytiga®) is a selective inhibitor of CYP17 and thereby inhibits androgen biosynthesis, with androgen signalling crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently, in the development of metastatic castration-resistant PC (mCRPC). In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in combination with prednisone was an effective treatment and had an acceptable, manageable tolerability and safety profile in chemotherapy-naive and docetaxel-experienced men with mCRPC. In the pivotal global phase 3 trials, relative to placebo (+prednisone), abiraterone acetate (+prednisone) prolonged overall survival (OS) at data maturity (final analysis) and radiographic progression-free survival (rPFS) at all assessed timepoints. Given its efficacy in prolonging OS and its convenient once-daily oral regimen, in combination with prednisone, abiraterone acetate is an important first-line option for the treatment of mCRPC.

Notes

Acknowledgments

During the peer review process, the manufacturer of abiraterone acetate was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/AB98F0605A2BB450.

References

  1. 1.
    World Cancer Research Fund International. Cancer facts and figures: worldwide data. 2012. http://www.wcrf.org. Accessed 6 Apr 2017.
  2. 2.
    Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–80.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Kapoor A, Wu C, Shayegan B, et al. Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J. 2016;10(11–12):E414–23.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Tsao CK, Galsky MD, Small AC, et al. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110(11):1580–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012;4(4):167–78.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hoy SM. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs. 2013;73(18):2077–91.CrossRefPubMedGoogle Scholar
  7. 7.
    European Medicines Agency. Zytiga 250 mg tablets: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 14 Jul 2017.
  8. 8.
    Janssen Biotech Inc. Zytiga® (abiraterone acetate) tablets: US prescribing information. 2016. https://www.zytiga.com/. Accessed 20 Mar 2017.
  9. 9.
    Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lam H-M, McMullin R, Nguyen HM, et al. Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-16-2054.Google Scholar
  11. 11.
    Tolcher AW, Chi KN, Shore ND, et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70(2):305–13.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chi KN, Spratlin J, Kollmannsberger C, et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol. 2015;55(12):1406–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Inoue K, Shishido A, Vaccaro N, et al. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing. Cancer Chemother Pharmacol. 2015;75(1):49–58.CrossRefPubMedGoogle Scholar
  14. 14.
    Marbury T, Lawitz E, Stonerock R, et al. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol. 2014;54(7):732–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Chi KN, Tolcher A, Lee P, et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71(1):237–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.CrossRefPubMedGoogle Scholar
  18. 18.
    Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014;66(5):815–25.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Ye D, Huang Y, Zhou F, et al. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian J Urol. 2017. doi: 10.1016/j.ajur.2017.01.002.Google Scholar
  22. 22.
    Sun Y, Zou Q, Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23(5):404–11.CrossRefPubMedGoogle Scholar
  23. 23.
    Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015;33(12):1356–63.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Attard G, de Bono JS, Logothetis CJ, et al. Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin Cancer Res. 2015;21(7):1621–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14(12):1193–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Cella D, Li S, Li T, et al. Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. J Community Support Oncol. 2016;14(4):148–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Smith MR, Rathkopf DE, Mulders PF, et al. Efficacy and safety of abiraterone acetate in elderly (75 years or older) chemotherapy naive patients with metastatic castration resistant prostate cancer. J Urol. 2015;194(5):1277–84.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bellmunt J, Kheoh T, Yu MK, et al. Prior endocrine therapy impact on abiraterone acetate clinical efficacy in metastatic castration-resistant prostate cancer: post-hoc analysis of randomised phase 3 studies. Eur Urol. 2016;69(5):924–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Saad F, Shore N, Van Poppel H, et al. Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015;68(4):570–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    de Bono JS, Smith MR, Saad F, et al. Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;71(4):656–64.CrossRefPubMedGoogle Scholar
  31. 31.
    Xu XS, Ryan CJ, Stuyckens K, et al. Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients. Clin Cancer Res. 2015;21(14):3170–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Goodman OB Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(1):34–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Mulders PFA, Molina A, Marberger M, et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol. 2014;65(5):875–83.CrossRefPubMedGoogle Scholar
  34. 34.
    Fizazi K, Flaig TW, Stockle M, et al. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016;27(4):699–705.CrossRefPubMedGoogle Scholar
  35. 35.
    Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015;33(12):1348–55.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Montgomery B, Kheoh T, Molina A, et al. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015;67(5):866–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Ryan CJ, Molina A, Li J, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013;31(22):2791–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Chi KN, Kheoh T, Ryan CJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27(3):454–60.CrossRefPubMedGoogle Scholar
  39. 39.
    Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;24(4):1017–25.CrossRefPubMedGoogle Scholar
  41. 41.
    Harland S, Staffurth J, Molina A, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013;49(17):3648–57.CrossRefPubMedGoogle Scholar
  42. 42.
    Sternberg CN, Castellano D, Daugaard G, et al. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014;15(11):1263–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Houede N, Beuzeboc P, Gourgou S, et al. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer. 2015;15:222.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Van Praet C, Rottey S, Van Hende F, et al. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program. Urol Oncol. 2016;34(6):254.e7–13.CrossRefGoogle Scholar
  45. 45.
    Pilon D, Behl AS, Ellis LA, et al. Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide. J Manag Care Spec Pharm. 2017;23(2):225–35.CrossRefPubMedGoogle Scholar
  46. 46.
    Azad AA, Eigl BJ, Leibowitz-Amit R, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol. 2015;67(3):441–7.CrossRefPubMedGoogle Scholar
  47. 47.
    European Medicines Agency. Zytiga-H-C-2321-II-0004-G: EPAR assessment report variation. 2013. http://www.ema.europa.eu. Accessed 14 Jul 2017.
  48. 48.
    Ruiz Gracia P, Dearden L, Antoni L, et al. Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment [abstract no. 738P]. Ann Oncol. 2016;27(Suppl. 6).Google Scholar
  49. 49.
    Moreira RB, Debiasi M, Maluf F, et al. Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials [abstract no. 73]. J Clin Oncol. 2016;34(2 Suppl.).Google Scholar
  50. 50.
    Janssen Pharma Co. Abiraterone acetate (Zaitiga®) 250 mg tablet: Japanese prescribing information. 2015. http://www.pmda.go.jp/. Accessed 21 May 2017.
  51. 51.
    Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMedGoogle Scholar
  52. 52.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. 2017. https://www.nccn.org. Accessed 20 Mar 2017.
  53. 53.
    Flaig TW, Potluri RC, Ng Y, et al. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5(2):182–91.CrossRefPubMedGoogle Scholar
  54. 54.
    Lafeuille MH, Grittner AM, Lefebvre P, et al. Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Pharm. 2014;20(5):477–84.Google Scholar
  55. 55.
    Ellis LA, Lafeuille MH, Gozalo L, et al. Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer. Am Health Drug Benefits. 2015;8(4):185–95.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Ramaekers BL, Riemsma R, Tomini F, et al. Abiraterone acetate for the treatment of chemotherapy-naive metastatic castration-resistant prostate cancer: an evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics. 2017;35(2):191–202.CrossRefPubMedGoogle Scholar
  57. 57.
    National Institute for Health and Clinical Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (NICE technology appraisal guidance 259). 2016. http://guidance.nice.org.uk/. Accessed 17 Jul 2017.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations